Literature DB >> 16849483

Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannose-binding lectin.

Itaru Terai1, Kunihiko Kobayashi, Jean-Pierre Vaerman, Naoki Mafune.   

Abstract

Mannose-binding lectin (MBL) is reported to bind to agalactosyl IgG, but not to normally galactosylated (native) IgG. It was recently reported that serum polymeric IgA in its native form reacts with MBL, whereas a more recent report has claimed that native IgD and IgE, and possibly IgM, do not. This led us to investigate whether IgA is truly reactive with MBL. To accomplish this, we collected purified human Igs, of various classes, subclasses, and allotypes, and tested their ability to bind to MBL using an ELISA method. Among these preparations, only one (monoclonal IgA2m(2):Kur) exhibited significant MBL binding. In particular, polymeric or monomeric forms of our normal serum IgA preparation lacked any ability to bind to MBL whatsoever. However, all the Ig preparations which had not bound to MBL became able to do so when they were degalactosylated with a galactosidase treatment, and the binding was further enhanced by acidic denaturation of the Igs. Among the degalactosylated and/or acid-denatured IgA, the IgA2 subclass exhibited a higher level of MBL binding than did IgA1. Our results suggest that MBL does not bind to native Igs (viewed in principle as "self" components), and that only Igs with abnormal glycosylation (degalactosylated forms) and/or denaturation would be MBL reactive.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849483     DOI: 10.4049/jimmunol.177.3.1737

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Authors:  Jennifer I Lai; Anna F Licht; Anne-Sophie Dugast; Todd Suscovich; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

Authors:  Margaret E Ackerman; Anne-Sophie Dugast; Elizabeth G McAndrew; Stephen Tsoukas; Anna F Licht; Darrell J Irvine; Galit Alter
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

3.  Immunoglobulin A Glycosylation and Its Role in Disease.

Authors:  Alyssa L Hansen; Colin Reily; Jan Novak; Matthew B Renfrow
Journal:  Exp Suppl       Date:  2021

4.  Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

Authors:  Nirmal K Banda; Allyson K Wood; Kazue Takahashi; Brandt Levitt; Pauline M Rudd; Louise Royle; Jodie L Abrahams; Gregory L Stahl; V Michael Holers; William P Arend
Journal:  Arthritis Rheum       Date:  2008-10

5.  Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection.

Authors:  Kazunori Murata; William M Baldwin
Journal:  Transplant Rev (Orlando)       Date:  2009-04-10       Impact factor: 3.943

6.  Epithelial cell-specific MyD88 signaling mediates ischemia/reperfusion-induced intestinal injury independent of microbial status.

Authors:  Marcus Mühlbauer; Ernesto Perez-Chanona; Christian Jobin
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

7.  Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis.

Authors:  Anand S Mehta; Ronald E Long; Mary Ann Comunale; Mengjun Wang; Lucy Rodemich; Jonathan Krakover; Ramila Philip; Jorge A Marrero; Raymond A Dwek; Timothy M Block
Journal:  J Virol       Date:  2007-11-28       Impact factor: 5.103

8.  Interleukin-17 receptor A (IL-17RA) as a central regulator of the protective immune response against Giardia.

Authors:  Oonagh Paerewijck; Brecht Maertens; Leentje Dreesen; Frederik Van Meulder; Iris Peelaers; Dariusz Ratman; Robert W Li; Erik Lubberts; Karolien De Bosscher; Peter Geldhof
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

Review 9.  Emerging immunotherapies for autoimmune kidney disease.

Authors:  Mary Helen Foster; Jeffrey Robinson Ord
Journal:  Hum Vaccin Immunother       Date:  2019-01-16       Impact factor: 4.526

10.  The Alternative Pathway Is Necessary and Sufficient for Complement Activation by Anti-THSD7A Autoantibodies, Which Are Predominantly IgG4 in Membranous Nephropathy.

Authors:  Pallavi Manral; Tiffany N Caza; Aaron J Storey; Laurence H Beck; Dorin-Bogdan Borza
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.